Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2023
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649Markus Moehler, Hong Xiao, Steven I Blum, et al.The New England Journal of Medicine|March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerRonan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.Future Oncology (London, England)|March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagusYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.Nature|March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancerKohei Shitara, Jaffer A Ajani, Markus Moehler, et al.Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.The New England Journal of Medicine|February 2, 2022
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell CarcinomaYuichiro Doki, Jaffer A Ajani, Ken Kato, et al.Pageof 2